Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that management will participate in the Guggenheim SMID Cap Biotech Conference, taking place February 5-6, 2025, in New York City.

Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim representative.

About Rezolute, Inc.

Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI. For more information, visit www.rezolutebio.com.

Contact:

Rezolute, Inc.
Christen Baglaneas
[email protected]
508-272-6717

You May Also Be Interested In

• American Fusion Inc. (OTC: AMFN) Receives FINRA Clearance of Form 211 Under SEC Rule 15c2-11
• Géopolitique Profonde (GPTV) Surpasses 800,000 YouTube Subscribers, Confirming Its Standing as France's Leading Independent Media Outlet on Wealth Protection
• Saratoga Investment Corp. Prices Public Offering of $85.0 Million 8.00% Notes Due 2031